Boston, MA 03/28/2014 (medicalmarijuanareporter) – Cannabis Science Inc (OTCMKTS:CBIS) is a major player in the industry whose roles include developing cannabis-based medicines to treat various illnesses. There is a huge demand for cannabis-based products, and if this trend continues, more investors in companies such as CBIS will enjoy increased and better return on investment, than they have probably ever done. In the US, the cannabis market is among the fastest growing, and is poised to keep growing at similar levels to the Smartphone industry. This is quite remarkable for something that users in the US and around the world have viewed negatively for the longest time.
In 2013 alone, close to $1.43 billion worth of legal marijuana was sold in the US. Analysts expect this figure to keep growing and that by the end of 2014, more than $2.34 billion worth of legal marijuana will have been sold around the US. With similar increases in North America, South America, Europe, and Asia, the cannabis market is poised to enjoy a period of high demands that it has never experienced before. Remember that the Smartphone industry has grown by around 46 percent between 2012 and 2013. Cannabis markets will almost double this amount in 2014 alone, thus reassuring investors in CBIS that the future indeed looks bright.
Cannabis Science Inc (OTCMKTS:CBIS) does not yet enjoy universal acceptance as a safe product to use. Therefore, if companies such as CBIS are to experience better growth, and its investors enjoy higher returns on investment, there is need for change in this industry. CBIS and its competitors must work hard to make Cannabis less harmful than it has been. It would be important for such companies to focus as well on making sure that the industry is not only more predictable, but also more profitable, since this is the only way of attracting new investors. Thus far, things seem to be going well for CBIS, but the real proof will come at the end of 2014 in form of cannabis sales.